Another KRAS mutation identified
In the realm of cancer research, mutations in the KRAS gene play a crucial role, with approximately 20-30% of all cancers harboring KRAS mutations. Particularly in lethal cancers like pancreatic, colorectal, and lung cancers, there is a significant prevalence of KRAS mutations. The KRAS protein acts like a molecular switch, toggling between inactive and active states. Oncogenic mutations, such as KRAS G12D, keep KRAS in a perpetually active state, driving uncontrolled cell growth and proliferation. While initially considered 'undruggable,' the KRAS G12C mutation has been successfully targeted by covalent inhibitors, opening up the possibility of directly targeting RAS. However, the applicability of these inhibitors to other KRAS variants has been uncertain.
In a recent study published in Nature Chemical Biology, researchers have introduced a novel approach to target another major KRAS variant, G12D, offering hope for treating a broader spectrum of patients with KRAS-mutant tumors. Through the development of a malolactone-containing probe called (R)-7, a stable and irreversible bond can be formed with the specific mutated aspartic acid residue at position 12 of KRAS G12D. This compound targets a pocket near the nucleotide-binding site of KRAS, similar to the mechanism employed by inhibitors like adagrasib and sotorasib, which target the G12C variant.
The study showcases the evolution of covalent inhibitors targeting KRAS mutations, with a focus on the unique challenge of targeting aspartic acid residues, which differ from the more commonly targeted cysteine residues. The researchers ingeniously designed (R)-7 to selectively react with the Asp12 sidechain of KRAS G12D, demonstrating potency in suppressing downstream signaling and cancer cell growth. This approach is significant as it opens up avenues for targeting non-nucleophilic amino acids such as aspartic acid, expanding the scope of covalent targeting strategies in cancer therapy.
While the potential of compounds like (R)-7 and MRTX1133 in treating KRAS G12D-positive cancers is promising, challenges such as therapeutic resistance and tumor microenvironment complexities need to be addressed. Ongoing human trials will provide insights into the efficacy of these inhibitors in clinical settings. Additionally, further optimization and testing of (R)-7-like compounds are necessary before they can be considered for clinical use, including evaluations of pharmacological parameters like absorption, distribution, metabolism, and excretion.
Overall, this study sets a foundation for the development of targeted cancer therapies aimed at KRAS G12D and paves the way for future advancements in the field of covalent targeting of specific KRAS variants. Just as inhibitors targeting KRAS G12C have led to clinical successes, this research may catalyze the next generation of therapies for KRAS-mutant cancers, bringing new hope to patients with these challenging malignancies.
Source: https://www.nature.com/articles/s41589-024-01556-x
In a recent study published in Nature Chemical Biology, researchers have introduced a novel approach to target another major KRAS variant, G12D, offering hope for treating a broader spectrum of patients with KRAS-mutant tumors. Through the development of a malolactone-containing probe called (R)-7, a stable and irreversible bond can be formed with the specific mutated aspartic acid residue at position 12 of KRAS G12D. This compound targets a pocket near the nucleotide-binding site of KRAS, similar to the mechanism employed by inhibitors like adagrasib and sotorasib, which target the G12C variant.
The study showcases the evolution of covalent inhibitors targeting KRAS mutations, with a focus on the unique challenge of targeting aspartic acid residues, which differ from the more commonly targeted cysteine residues. The researchers ingeniously designed (R)-7 to selectively react with the Asp12 sidechain of KRAS G12D, demonstrating potency in suppressing downstream signaling and cancer cell growth. This approach is significant as it opens up avenues for targeting non-nucleophilic amino acids such as aspartic acid, expanding the scope of covalent targeting strategies in cancer therapy.
While the potential of compounds like (R)-7 and MRTX1133 in treating KRAS G12D-positive cancers is promising, challenges such as therapeutic resistance and tumor microenvironment complexities need to be addressed. Ongoing human trials will provide insights into the efficacy of these inhibitors in clinical settings. Additionally, further optimization and testing of (R)-7-like compounds are necessary before they can be considered for clinical use, including evaluations of pharmacological parameters like absorption, distribution, metabolism, and excretion.
Overall, this study sets a foundation for the development of targeted cancer therapies aimed at KRAS G12D and paves the way for future advancements in the field of covalent targeting of specific KRAS variants. Just as inhibitors targeting KRAS G12C have led to clinical successes, this research may catalyze the next generation of therapies for KRAS-mutant cancers, bringing new hope to patients with these challenging malignancies.
Source: https://www.nature.com/articles/s41589-024-01556-x
Comments
Post a Comment